# Biotech Daily Digest ‚Äî 2026-01-02

**4 items from 3 sources**

## Summary by Source

- Endpoints News: 1 item
- Fierce Biotech: 2 items
- MHRA ‚Äì News: 1 item


## Endpoints News

- **[FDA again rejects Outlook's wet AMD drug; Chinese siRNA biotech expects $188M IPO](https://endpoints.news/ask-pharm-makes-china-rights-deal-unicycive-resubmits-kidney-drug-after-crl/)**  
  _Mon, 29 Dec 2025 17:42:33 +0000_  
  Plus, news about InflaRx, ASK Pharm, Unicycive, Harbour BioMed, Omeros, Gilead, Repare Therapeutics, Vaccinex and Foresee Pharmaceuticals.

 üëÅÔ∏è FDA rejects Outlook Therapeutics' version of Avastin for third time: The agency


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/ultragenyx-plans-major-cost-cutting-push-after-flunking-phase-3-brittle-bone-trials" hreflang="en">Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials</a>](https://www.fiercebiotech.com/biotech/ultragenyx-plans-major-cost-cutting-push-after-flunking-phase-3-brittle-bone-trials)**  
  _Jan 2, 2026 5:37am_  
  Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.

- **[<a href="https://www.fiercebiotech.com/biotech/biohaven-flunks-phase-2-depression-trial-adding-concerns-pivotal-readout" hreflang="en">Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout</a>](https://www.fiercebiotech.com/biotech/biohaven-flunks-phase-2-depression-trial-adding-concerns-pivotal-readout)**  
  _Jan 2, 2026 4:49am_  
  As the biopharma wound down for the holidays, the company¬†reported the failure of a midphase study of BHV-7000 for the treatment of major depressive disorder.


## MHRA ‚Äì News

- **[MHRA approves zapomeran (Kostaive) mRNA COVID-19 vaccine](https://www.gov.uk/government/news/mhra-approves-zapomeran-kostaive-mrna-covid-19-vaccine)**  
  _2026-01-02T13:37:25Z_  
  As with any medicine, the MHRA will keep the safety and effectiveness of zapomeran under close review.
